TG Therapeutics Inc. Common Stock (TGTX)

FairStock Score: 65/100 — STEADY

Key Financials

Strengths

• High return on equity of 102.8% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.39, providing financial flexibility
• Altman Z-Score of 8.1 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 78.0% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($16) with negative 133% margin of safety—limited downside protection

AI Analysis

TG Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $6.0 billion. The business generates $616 million in annual revenue with a 3.7% net margin. From a quality standpoint, TG shows Altman Z-Score of 8.1 confirms fortress-level solvency and extraordinary 103% return on equity. On valuation, the stock is attractively valued at 13.3x earnings, with trades far above its Graham Number ($16) with no margin of safety. Growth dynamics show revenue growing at 78.0% and profit growth of -1.3%. Our composite FairStock Score of 65/100 reflects above-average fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

TG's 78% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer